Publications by authors named "Boguniewicz M"
Atopic dermatitis (AD), a common chronic inflammatory skin disorder is characterized by a complex pathology with skin-barrier abnormalities, immune dysregulation, and microbial dysbiosis. Patients' quality of life is often negatively impacted by persistent pruritus, sleep disturbance, and recurrent skin infections. In addition, patients may have comorbid atopic as well as nonatopic diseases.
View Article and Find Full Text PDFArticle Synopsis
- Atopic dermatitis (AD) significantly affects patients' quality of life, causing itching, skin pain, and sleep disturbances; ruxolitinib cream has shown effectiveness in treating these symptoms in adults and adolescents through two phase III clinical trials.
- In the TRuE-AD studies, patients applied different strengths of ruxolitinib cream or a vehicle cream, with results indicating that those using ruxolitinib experienced quick relief from symptoms like skin pain and sleep issues within hours or weeks of application.
- Analysis of patient-reported outcomes revealed notable improvements in overall quality of life and symptom burden after two weeks of using ruxolitinib cream compared to the vehicle, with sustained benefits observed throughout the study periods.
Corrigendum to <'A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology'> <[Annals of Allergy, Asthma & Immunology 133 (2024) 286-94]>.
Ann Allergy Asthma Immunol
November 2024
Article Synopsis
- The study investigates how type 2 comorbidities like asthma, allergic rhinitis, and food allergies affect the treatment response to dupilumab in young children with atopic dermatitis.
- In a trial involving children aged 6 months to 5 years, results showed that those treated with dupilumab had significantly better outcomes compared to those on placebo, regardless of comorbidities.
- Overall, the treatment was found to be safe and effectively improved symptoms of atopic dermatitis in children, supporting its use in those with and without type 2 inflammatory conditions.
Article Synopsis
- * Mild-to-moderate AD is typically treated with topical anti-inflammatory medications and basic skin care, while moderate-to-severe cases often need systemic therapy, including off-label immunosuppressants, which carry safety concerns.
- * New targeted biologics and small molecules are emerging as more effective and safer treatment options for AD, leading to the development of standardized recommendations for treating pediatric patients with moderate-to-severe cases.
Article Synopsis
- The disease is complex, involving issues like skin barrier dysfunction, immune system imbalances, and changes in skin microbes, which all contribute to its symptoms.
- Treatments currently available include monoclonal antibodies like Dupilumab and tralokinumab for moderate-to-severe cases, with additional medications like lebrikizumab and nemolizumab in the pipeline.
CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity.
J Allergy Clin Immunol
September 2024
Article Synopsis
- Atopic dermatitis (AD) is an inflammatory skin condition linked to varying levels of Staphylococcus aureus, which affects disease severity and responds to treatments like dupilumab.
- This study aimed to identify host genes related to S aureus levels and AD severity using data from a clinical trial involving 71 adults with moderate-to-severe AD.
- The findings revealed a positive correlation between CERS1 expression (a gene associated with skin lipids) and both S aureus abundance and AD severity, suggesting CERS1 could serve as a biomarker for skin barrier dysfunction, with changes observable after dupilumab treatment.
Article Synopsis
- * The American Academy of Allergy, Asthma & Immunology has released updated guidelines for treating atopic dermatitis, focusing on trustworthy development standards and evidence-based medicine to guide clinical decisions.
- * The guidelines include recommendations for various treatments like topical therapies, dietary changes, and systemic treatments, emphasizing the importance of considering patient values and preferences in treatment selection.
Article Synopsis
- Pediatric patients with moderate-to-severe atopic dermatitis (AD) showed elevated inflammatory biomarkers, which dupilumab treatment aimed to reduce.
- In a study involving various age groups, patients received either dupilumab or a placebo, leading to significant reductions in biomarkers such as TARC/CCL17, total IgE, and lactate dehydrogenase (LDH) after 16 weeks.
- The results indicate that dupilumab effectively minimizes inflammation in these patients, reaching levels similar to healthy individuals.
Article Synopsis
- - Dupilumab is a monoclonal antibody used to treat conditions like asthma and atopic dermatitis, but its use in clinical trials led to recommendations against live vaccines due to safety concerns.
- - Recent systematic reviews and an expert panel concluded that live vaccines are generally safe for patients on dupilumab and that the effectiveness of vaccines is not compromised.
- - It is advisable for clinicians and patients to engage in shared decision-making regarding the administration of vaccines to those receiving dupilumab.
Article Synopsis
- The aryl hydrocarbon receptor (AhR) is a transcription factor involved in inflammation and homeostasis, responding to various endogenous and environmental ligands.
- AhR's widespread expression and regulatory capabilities position it as a promising target for therapies, particularly in treating inflammatory skin conditions like psoriasis and atopic dermatitis.
- Tapinarof cream, a nonsteroidal topical AhR agonist, has shown significant efficacy in clinical trials and suggests potential use in other inflammatory diseases due to shared pathogenetic traits.
Article Synopsis
- The American Academy of Allergy, Asthma, and Immunology is updating its guidelines for managing atopic dermatitis (AD) due to advancements in treatment and evidence methods since the last update in 2012.
- A multidisciplinary panel, including AD specialists and patient representatives, created evidence-based guidelines emphasizing equity, diversity, and minimizing conflicts of interest while reviewing systematic evidence.
- The panel produced 25 recommendations to help manage AD and included practical implementation resources for patients, covering various treatment options like topical corticosteroids, calcineurin inhibitors, and more.
Article Synopsis
- Atopic dermatitis (AD) is a skin condition that causes inflammation and can be treated in different ways, but it's not always clear which treatments work best.
- Researchers looked at many studies to compare the benefits and risks of different treatments for AD.
- They found that some treatments, like high-dose upadacitinib, were very effective but also had more side effects, while others like dupilumab were safer but less powerful.
Article Synopsis
- Atopic dermatitis (AD) is a widespread skin condition treated with various topical prescriptions, but their comparative effectiveness is not well known.
- A systematic review of randomized trials was conducted to evaluate the benefits and harms of topical treatments for AD, employing rigorous analysis and classification methods.
- High-certainty evidence showed that pimecrolimus and high-dose tacrolimus were highly effective, while group 5 topical corticosteroids (TCS) also significantly aided in managing AD without increasing harm.
The role of Janus kinase signaling in the pathology of atopic dermatitis.
J Allergy Clin Immunol
December 2023
Article Synopsis
- * The disease involves complex interactions between immune system dysfunction, genetics, and environmental factors, with various cytokines like IL-4 and IL-13 playing key roles in its development.
- * This review focuses on the JAK-STAT signaling pathway, especially JAK1, to better understand its contributions to the symptoms and mechanisms behind atopic dermatitis.
Article Synopsis
- * Tralokinumab is a new monoclonal antibody that targets IL-13, showing significant improvements in AD symptoms in three phase 3 clinical trials, both alone and with topical corticosteroids.
- * Treatment with tralokinumab leads to noticeable symptom relief, including reduced itch and better sleep, while maintaining a safety profile similar to a placebo, making it a strong new option for managing moderate-to-severe AD.
Article Synopsis
- - Atopic dermatitis (AD) is an inflammatory skin disorder linked to type 2 inflammation and Staphylococcus aureus infections, which contribute to the disease severity.
- - A study involving 71 participants with moderate-severe AD showed that treatment with dupilumab, a type 2 inflammatory blockade, significantly reduced S aureus levels within just 3 days, preceding clinical improvements by 11 days.
- - The reduction in S aureus was associated with decreased levels of the biomarker CCL17 and improvements in AD severity, suggesting that T17 cells, neutrophils, and complement pathways may play a role in the treatment's effectiveness.
Article Synopsis
- The study explored atopic dermatitis (AD), a chronic skin condition, to link its severity with historical and clinical features as well as biomarkers.
- A total of 2,862 participants were categorized into mild, moderate, and severe AD, with findings showing that severity is associated with several factors including a personal/family history of allergic disorders and certain skin conditions.
- Key indicators of severity included high serum IgE levels, eosinophilia, and specific skin manifestations, along with a range of bacterial and viral skin infections, highlighting the complex nature of AD.
Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin.
J Allergy Clin Immunol Pract
May 2023
Article Synopsis
- Atopic dermatitis (AD) is linked to skin issues like oozing and bleeding, suggesting vascular changes, which are targeted by the treatment dupilumab, an IL-4 receptor antibody.
- A study assessed the impact of dupilumab on vascular barrier function by analyzing plasma protein levels in AD patients before and after 16 weeks of treatment compared to healthy individuals.
- Results showed that dupilumab significantly reduced elevated plasma proteins in AD skin, bringing levels closer to those found in healthy skin and potentially decreasing factors that worsen AD severity and bacterial colonization.
Article Synopsis
- The study aims to synthesize patient and caregiver values and preferences in managing atopic dermatitis (AD) to aid the development of clinical guidelines by relevant allergy associations.* ! -
- A thorough review of numerous studies revealed that participants generally favor starting with nonmedical treatments and are concerned about side effects from medications, highlighting the importance of a strong patient-clinician relationship.* ! -
- Findings indicate that patients prefer treatments that are odorless, minimally visible, and have a low impact on daily activities, with a specific emphasis on relieving itching and burning sensations.* !
Article Synopsis
- A study was conducted to evaluate the long-term efficacy of baricitinib 2 mg in adults with moderate-to-severe atopic dermatitis (AD) over a 52-week period as part of the BREEZE-AD6 trial after patients participated in the initial BREEZE-AD5 study.
- Results showed that after 52 weeks, 48.6% of patients achieved a significant improvement (75% reduction) in their eczema symptoms (EASI75), and 31.3% had clear or almost clear skin based on the vIGA-AD scoring.
- Patient-reported outcomes reflected sustained improvements in symptoms like itch and sleep quality, as well as overall quality of
Article Synopsis
- Adults with atopic dermatitis (AD) may experience the condition differently based on whether it started in childhood or adulthood, but the study aimed to find out how effective the treatment dupilumab is for both groups.
- The analysis involved 917 patients (460 on placebo and 457 on dupilumab), with results showing that dupilumab greatly improved AD symptoms after 16 weeks, regardless of when the disease began.
- Overall, dupilumab was effective in providing symptom relief and enhancing quality of life for all patients, indicating its broad applicability in treating adults with AD regardless of age of onset.
Article Synopsis
- Atopic dermatitis (AD) is influenced by skin barrier issues, immune responses, and factors like allergens, but the specific role of environmental allergens in aggravating AD is not well understood.
- A study reviewed 23 randomized controlled trials to assess the benefits and harms of allergen immunotherapy (AIT) like subcutaneous (SCIT) and sublingual (SLIT) therapies for easing AD symptoms and improving quality of life (QoL).
- Results indicated that both SCIT and SLIT significantly improve AD severity and QoL but also lead to more adverse events, suggesting that while they can help manage symptoms, there are trade-offs to consider.